Denali Therapeutics closes down 11% as 2025 operating expenses seen weighing
Source: SeekingAlpha
2025-02-28 16:54:15 ET
More on Denali Therapeutics
- Denali: Despite ALS Primary Endpoint Failure, Possible Path Forward Remains
- Denali Therapeutics gets FDA breakthrough therapy designation for its treatment of hunter syndrome
- Denali ALS candidate fails in key study
- Seeking Alpha’s Quant Rating on Denali Therapeutics
- Historical earnings data for Denali Therapeutics
Read the full article on Seeking Alpha
For further details see:
Denali Therapeutics closes down 11% as 2025 operating expenses seen weighing
Denali Therapeutics Inc.
NASDAQ: DNLI
DNLI Trading
-1.27% G/L:
$20.25 Last:
349,466 Volume:
$20.91 Open:
DNLI Latest News
February 26, 2026 04:01:00 pm
Denali Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
February 19, 2026 08:30:00 am
Drug-Delivery Breakthroughs, Cross-Indication Research Accelerate New Momentum in CNS and Oncology Development
DNLI Stock Data
$3,127,833,066
136,297,507
0.26%
87
N/A
Biotechnology & Life Sciences
Healthcare
US
South San Francisco
